- Home
- YHGJ vs APLM Comparison
YHGJ vs APLM Comparison
Compare YHGJ & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- APLM
- Stock Information
- Founded
- YHGJ 1975
- APLM 2016
- Country
- YHGJ United States
- APLM United States
- Employees
- YHGJ N/A
- APLM N/A
- Industry
- YHGJ Specialty Chemicals
- APLM Blank Checks
- Sector
- YHGJ Industrials
- APLM Finance
- Exchange
- YHGJ Nasdaq
- APLM Nasdaq
- Market Cap
- YHGJ 22.5M
- APLM 6.9M
- IPO Year
- YHGJ 1997
- APLM N/A
- Fundamental
- Price
- YHGJ $0.73
- APLM $6.49
- Analyst Decision
- YHGJ
- APLM
- Analyst Count
- YHGJ 0
- APLM 0
- Target Price
- YHGJ N/A
- APLM N/A
- AVG Volume (30 Days)
- YHGJ 6.0K
- APLM 7.8K
- Earning Date
- YHGJ 05-20-2025
- APLM 08-13-2025
- Dividend Yield
- YHGJ N/A
- APLM N/A
- EPS Growth
- YHGJ N/A
- APLM N/A
- EPS
- YHGJ N/A
- APLM N/A
- Revenue
- YHGJ $17,861,000.00
- APLM $198,000.00
- Revenue This Year
- YHGJ N/A
- APLM $415.15
- Revenue Next Year
- YHGJ N/A
- APLM N/A
- P/E Ratio
- YHGJ N/A
- APLM N/A
- Revenue Growth
- YHGJ 1.21
- APLM N/A
- 52 Week Low
- YHGJ $0.43
- APLM $4.47
- 52 Week High
- YHGJ $1.37
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- YHGJ 47.03
- APLM 47.85
- Support Level
- YHGJ $0.71
- APLM $6.21
- Resistance Level
- YHGJ $0.85
- APLM $6.80
- Average True Range (ATR)
- YHGJ 0.07
- APLM 0.52
- MACD
- YHGJ 0.01
- APLM 0.00
- Stochastic Oscillator
- YHGJ 41.20
- APLM 51.61
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.